Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal Inovasi Farmasi Indonesia
Ratnanigrum, Elly Rakhmawati
Unknown Affiliation
Decision Sciences, Operations Research & Management Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Analisis Profil Terapi dan Evaluasi Kualitas Peresepan Pada Pasien COVID-19 Rawat Inap di Rs X Jawa Tengah: Therapeutic Profile Analysis and Prescription Quality Assessment for COVID-19 Inpatients Hospital X in East Java Mawarni, Okky Intan; winartiana, Winartiana; Putri, Elsa Mahardika; Pratiwi, Maharani Dwi; Prabowo, Pulung; Ratnanigrum, Elly Rakhmawati
Jurnal Inovasi Farmasi Indonesia (JAFI) Vol. 6 No. 2 (2025): Volume 6, No.2 Juni 2025
Publisher : Universitas Kadiri

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30737/jafi.v6i2.6530

Abstract

COVID-19, caused by SARS-CoV-2, has a high transmission and mortality rate, The variability in therapies administered to patients necessitates an evaluation of treatment patterns among COVID-19 patients to ensure effective therapeutic outcomes. This study aims to analyze the therapy profiles and evaluate prescription patterns of hospitalized patients at General Hospital X, Central Java, based on the COVID-19 Management Protocol, 2nd edition (January 2021). A retrospective descriptive method with purposive sampling was applied to 100 hospitalized COVID-19 patients in 2022. The results showed that the majority of patients were male (55%), aged 40–59 years (45%), had moderate disease severity (77%), a treatment duration of 1–10 days (89%), and a recovery rate of 62%. The most frequently used drug therapies included respiratory medications (19%), gastrointestinal drugs (17%), vitamins (16%), antibiotics (11%), and antivirals (11%). Prescription evaluation revealed 100% drug suitability, 100% correct dosage, 97% appropriate dosing intervals, and 92% correct duration of administration.
Co-Authors Mawarni, Okky Intan prabowo, pulung Pratiwi, Maharani Dwi Putri, Elsa Mahardika Winartiana, Winartiana